Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia

Haematologica

Volumn 93, Issue 8, 2008, Pages 1260-1261

  Ricksten, Anne ^a   Palmqvist, Lars ^a   Johansson, Peter ^a,b   Andreasson, Björn ^a,b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UDDEVALLA HOSPITAL   (Sweden)

Author keywords

Essential thrombocythemia; Eydroxyurea; JAK2V617F; Polycythemia vera; Treatment effect

Indexed keywords

ACETYLSALICYLIC ACID; HEMOGLOBIN; HYDROXYUREA; JANUS KINASE; PEGINTERFERON;

ADULT; AGED; BONE MARROW SUPPRESSION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; DNA EXTRACTION; DRUG EFFECT; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; LEUKOCYTE COUNT; MALE; PHLEBOTOMY; POLYCYTHEMIA VERA; THROMBOCYTE COUNT; THROMBOCYTHEMIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANTISICKLING AGENTS; FEMALE; HUMANS; HYDROXYUREA; JANUS KINASE 2; LEUKOCYTE COUNT; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; POLYMORPHISM, SINGLE NUCLEOTIDE; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 48749127301     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12801     Document Type: Letter

References (10)

1. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
2. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-6.
3. Swedish Society of Hematology. Available from: http://www.sfhem.se/ filarkiv/files/vardprogram/NMPDGui delines2007.pdf.
4. Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a. Blood 2006;108:2037-40.
5. Jones AV, Silver RT, Waghorn K, Curtis C, Kreil S, Zoi K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 2006;107:3339-41.
6. Samuelsson J, Mutschler M, Birgegård G, Gram-Hansen P, Björkholm M, Pahl HL. Limited effects on JAK2 mutational status after pegylated interferon α-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica 2006;91:1281-2.
7. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-53.
8. Pemmaraju N, Moliterno AR, Williams DM, Rogers O, Spivak JL. The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. Leukemia 2007;21:2210-2.
9. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007;2:1952-9.
10. Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 2008; 93:41-8.